Kelly CRISPR & Gene Editing Technology ETF Rating $7.38 0.00 (0.00%) (As of 11/1/2024 ET) Add Compare Share Share Ratings Stock AnalysisChartHeadlinesOptions ChainRatingsTrends Kelly CRISPR & Gene Editing Technology ETF Aggregate Rating and Price Target (2024)How MarketBeat Aggregates ETF Rating and Price TargetMarketBeat calculates the aggregate rating and price target for an ETF by considering the weight of each stock in its portfolio. These ratings and price targets are based on the most recent ratings given by Wall Street analysts over the past year. The aggregate rating reviews the ETF's overall performance and is categorized as strong sell, sell, reduce, hold, moderate buy, buy, or strong buy. The aggegreate price target represents the average potential upside for the consensus price target of individual holdings in the ETF.XDNA Aggregate RatingModerate Buy2.68Holdings in XDNA have an aggregate rating of Moderate Buy based on 283 analyst ratings issued in the past year covering 21 companies (94.6% of the portfolio).XDNA Aggregate Price Target$19.88169.39% UpsideHigh Prediction$31.86Average Prediction$19.88Low Prediction$9.34Holdings in XDNA have an aggregate price target of $19.88 and a range of $9.34 to $31.86 covering 21 companies (94.6% of the portfolio).XDNA Consensus Ratings of HoldingsStrong Buy0 Strong Buy rating(s)Buy3 Buy rating(s)Moderate Buy13 Moderate Buy rating(s)Hold4 Hold rating(s)Reduce1 Reduce rating(s)Sell0 Sell rating(s)Strong Sell0 Strong Sell rating(s) Ratings for Stocks Held by Kelly CRISPR & Gene Editing Technology ETF Strong Sell Sell Reduce Hold Moderate Buy Buy Strong Buy Ratings for the Top 21 XDNA Holdings Export to ExcelWeight In ETFCompanyShare PriceMarketRank™Consensus Rating ScoreConsensus Price TargetPossible UpsideNumber of RatingsIndicator(s)ViewRatings11.05%NTLAIntellia Therapeutics$14.81+4.1%4.2677 of 5 stars2.76$59.13 299.3%1710.70%TMOThermo Fisher Scientific$557.92+2.1%4.964 of 5 stars2.86$649.33 16.4%22Insider Selling9.57%BEAMBeam Therapeutics$22.93+4.7%3.0205 of 5 stars2.60$45.80 99.7%10Upcoming Earnings8.64%CRSPCRISPR Therapeutics$50.76+9.4%2.7649 of 5 stars2.37$75.19 48.1%19Upcoming EarningsAnalyst Upgrade6.78%CRBUCaribou Biosciences$2.21+12.8%2.1123 of 5 stars2.75$11.25 409.0%4Upcoming Earnings5.63%VERVVerve Therapeutics$5.93+3.5%2.3172 of 5 stars3.00$26.00 338.4%5Upcoming Earnings5.16%SGMOSangamo Therapeutics$1.88+10.6%1.9178 of 5 stars2.25$2.67 41.8%4Upcoming EarningsGap Up4.73%PRMEPrime Medicine$4.03+3.9%2.9549 of 5 stars2.89$13.50 235.0%94.37%ABBVAbbVie$203.55-0.2%4.8499 of 5 stars2.84$201.00 -1.3%19Earnings ReportDividend IncreaseAnalyst ForecastShort Interest ↑Analyst RevisionNews Coverage4.13%EDITEditas Medicine$2.91+0.3%4.6753 of 5 stars2.45$9.91 240.5%11Short Interest ↑4.10%ALLOAllogene Therapeutics$2.72+6.7%2.9985 of 5 stars2.73$9.96 266.0%11Upcoming EarningsAnalyst ForecastNews Coverage3.32%PSTXPoseida Therapeutics$2.47+4.2%3.645 of 5 stars3.00$15.00 507.3%2Analyst Forecast2.96%DTILPrecision BioSciences$9.02+5.4%4.0207 of 5 stars3.00$39.50 337.9%2Upcoming Earnings2.87%TSVT2seventy bio$4.40+1.4%1.7712 of 5 stars2.56$9.00 104.5%92.40%AAgilent Technologies$136.87+5.0%4.5796 of 5 stars2.50$144.36 5.5%14Positive NewsGap Up2.10%BMYBristol-Myers Squibb$54.32-2.6%4.5139 of 5 stars1.93$53.00 -2.4%14Earnings ReportAnalyst ForecastShort Interest ↑Analyst RevisionNews Coverage2.00%ILMNIllumina$149.76+3.9%4.153 of 5 stars2.67$154.33 3.1%24Upcoming Earnings1.53%VRTXVertex Pharmaceuticals$471.12-1.0%3.4466 of 5 stars2.48$492.50 4.5%29Upcoming EarningsAnalyst Forecast1.29%REGNRegeneron Pharmaceuticals$843.60+0.6%4.8453 of 5 stars2.73$1,090.24 29.2%22Analyst ForecastAnalyst RevisionNews Coverage0.69%QGENQiagen$43.08+2.3%3.9429 of 5 stars2.60$50.88 18.1%10Upcoming Earnings0.57%BIIBBiogen$173.79-0.1%4.8404 of 5 stars2.62$262.83 51.2%26Earnings ReportAnalyst ForecastShort Interest ↑Analyst RevisionNews Coverage This page (NASDAQ:XDNA) was last updated on 11/2/2024 by MarketBeat.com Staff From Our PartnersEx WH Advisor Who Predicted Biden Leaving Race Makes Startling New PredictionFormer advisor to the CIA, the Pentagon and the White House Jim Rickards went on multiple TV news programs… ...Paradigm Press | Sponsored625,000% GainImagine swapping your daily coffee expense for a future free of financial worries. It might seem far-fetche...Crypto Swap Profits | SponsoredSell NVDA Now?Guess who's selling NVDA next The most successful hedge fund in history quietly sold 500,000 shares. Here's...Chaikin Analytics | SponsoredMarket "Famine" ComingMarket Wizard Larry Benedict accurately predicted that all indexes would be negative in 2022... He predicte...Opportunistic Trader | SponsoredThe centerpiece of Trump’s crypto’s masterplan …Donald Trump wants to be America’s first crypto president. He was the keynote speaker at the recent Bitcoin...Weiss Ratings | SponsoredHow Will You Survive A Post Election Retirement Heist?The clock is ticking, and your life savings are in an extremely vulnerable position. We are a few days away...American Hartford Gold Group | SponsoredBlackrock’s Sending THIS Crypto Higher on PurposeIt's a groundbreaking opportunity that could be poised for extraordinary gains. The catalyst behind this su...Crypto 101 Media | SponsoredI was wrong. Dead wrong. I thought what happened 25 years ago was a once- in-a-lifetime event… but how wrong I was. Because here we...Porter & Company | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Kelly CRISPR & Gene Editing Technology ETF Please log in to your account or sign up in order to add this asset to your watchlist. Share Kelly CRISPR & Gene Editing Technology ETF With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
